A new trial based on real-world evidence compared cholesterol-lowering therapies in reducing heart-attack risk, with injectable evolocumab (Repatha) outperforming oral ezetimibe. The STAT+ report frames the findings as a direct head-to-head between the PCSK9 inhibitor and the oral cholesterol absorption inhibitor, both used when statins alone are insufficient. The reported effect was a roughly 20% reduction in heart-attack risk with evolocumab. For clinicians and payers, the result strengthens the case for selecting therapy based on comparative event outcomes rather than LDL-lowering alone.